ArticleFrontiers in psychiatry2025
Lurasidone induces developmental toxicity and behavioral impairments in zebrafish embryos.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lurasidone, a second-generation antipsychotic widely used for schizophrenia and bipolar disorder due to its favorable metabolic profile, has poorly understood potential developmental neurotoxicity. This study investigated its effects on zebrafish embryos to address this gap. Methods: Zebrafish embryos were exposed to lurasidone at concentrations of 0, 0.4, 4, and 8 mg/L from 5 to 120 hours post-fertilization (hpf). We integrated morphological assessments, behavioral analyses, transcriptomic profiling, and neurotransmitter quantification to evaluate developmental neurotoxicity. Results: Lurasidone induced dose-dependent developmental toxicity, including reduced survival and hatching rates, decreased body length, and increased pericardial and yolk sac edema. Behavioral assessments revealed significant locomotor impairment and diminished touch response, especially at higher concentrations. Transcriptomic analysis identified 1,907 differentially expressed genes, with upregulation in circadian regulation pathways and downregulation in cell cycle and oxidative phosphorylation pathways. Neurotransmitter profiling showed significant reductions in glutamate, dopamine, and GABA levels. Discussion: These findings demonstrate lurasidone's potential to disrupt neurodevelopment, suggesting perturbations in excitatory/inhibitory neurotransmitter balance and critical cellular pathways. The results highlight neurodevelopmental risks during sensitive periods, underscoring the need for further safety assessment in vulnerable populations (e.g., pregnant women, young patients).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.